CRISPR Therapeutics (CRSP) Financials: History & Chart

CRISPR Therapeutics AG(CRSP)

Biotechnology · Zug, ZG

$55.43-0.01 (-0.02%)

Delayed quote: Oct 2, 2026, 4:00 PM EDT

About CRISPR Therapeutics AG

CRISPR Therapeutics AG (CRSP) is a biotechnology firm dedicated to pioneering gene-based medicines for severe diseases. The company achieves this through its exclusive Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) technology, which enables precise and targeted alterations to an organism's genetic code. Its extensive pipeline includes therapeutic candidates spanning multiple medical areas, such as blood disorders (hemoglobinopathies), various cancers (oncology), regenerative medicine, and rare conditions. The company's flagship investigational therapy is CTX001, an ex vivo CRISPR gene-edited treatment. This therapy aims to benefit patients with transfusion-dependent beta-thalassemia or severe sickle cell disease by modifying their own hematopoietic stem cells to markedly boost the production of fetal hemoglobin within red blood cells. CRISPR Therapeutics is also advancing several other genetically engineered allogeneic (donor-sourced) CAR-T investigational therapies: CTX110, designed to combat cluster of differentiation 19-positive malignancies; CTX120, which targets B-cell maturation antigen for multiple myeloma that has relapsed or proven resistant to previous treatments; and CTX130, focused on Cluster of Differentiation 70 for a spectrum of solid tumors and blood cancers. Furthermore, the company is developing VCTX210, an immune-evasive, gene-edited stem cell-derived product candidate for treating type 1 diabetes. It is also pursuing various in vivo gene-editing initiatives aimed at addressing disorders affecting the liver, lungs, muscles, and central nervous system. The company has forged strategic alliances with significant partners, including Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was established in 2013 and maintains its headquarters in Zug, Switzerland.

Zug, ZG

393 employees

www.crisprtx.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Samarth Kulkarni

View full financials

Financials

SEC Filings

Quarterly Income Statement (USD)

Swipe horizontally to review earlier periods. The line-item column stays pinned.

Quarterly Report	TTM	Quarter ended Jun 2026	Quarter ended Mar 2026	Quarter ended Dec 2025	Quarter ended Sep 2025	Quarter ended Jun 2025	Quarter ended Mar 2025	Quarter ended Dec 2024	Quarter ended Sep 2024
Revenue	13.39M	10.18M	1.46M	864K	889K	892K	865K	35.00M	602K
Cost of Goods Sold	218.88M	44.57M	50.25M	59.36M	64.69M	49.75M	57.51M	0.00	15.95M
Gross Profit	-205.49M	-34.39M	-48.79M	-58.50M	-63.80M	-48.86M	-56.64M	35.00M	-15.35M
Gross Profit Margin	-1534.4%	-337.8%	-3346.4%	-6770.8%	-7177.1%	-5477.7%	-6548.4%	100.0%	-2550.0%
Total Operating Expenses	326.38M	80.41M	81.46M	96.26M	68.25M	84.21M	91.78M	99.59M	94.78M
Research & Development	270.29M	64.95M	68.57M	77.86M	58.90M	65.29M	72.48M	82.16M	77.36M
Selling, General & Administrative	67.97M	15.45M	17.18M	18.40M	16.93M	18.92M	19.30M	18.12M	17.42M
Operating Income (EBIT)	-531.87M	-114.80M	-130.25M	-154.76M	-132.06M	-133.07M	-148.42M	-64.59M	-110.13M
Operating Margin	-3971.5%	-1127.6%	-8933.3%	-17912.5%	-14854.8%	-14918.3%	-17158.8%	-184.5%	-18294.0%
Income Before Tax (EBT)	-448.11M	-90.19M	-122.09M	-130.00M	-105.82M	-207.26M	-134.89M	-36.61M	-85.07M
Interest Income	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Other Income/Expense	83.76M	24.60M	8.16M	24.77M	26.24M	-74.19M	13.54M	27.98M	25.06M
Net Income	-451.14M	-91.15M	-122.93M	-130.61M	-106.44M	-208.55M	-136.00M	-37.31M	-85.94M
Income Tax Expense	3.03M	960K	839K	614K	619K	1.29M	1.11M	700K	876K
Net Profit Margin	-3368.7%	-895.3%	-8431.5%	-15117.2%	-11973.1%	-23379.9%	-15722.1%	-106.6%	-14276.1%
EBITDA	-513.15M	-110.50M	-125.93M	-149.10M	-127.63M	-128.47M	-143.69M	-59.75M	-105.39M
EBITDA Margin	-3831.8%	-1085.3%	-8637.1%	-17257.3%	-14356.1%	-14402.6%	-16611.3%	-170.7%	-17506.8%
Depreciation & Amortization	18.71M	4.30M	4.32M	5.66M	4.43M	4.60M	4.74M	4.84M	4.74M
EPS Basic	-4.76	-0.94	-1.28	-1.37	-1.17	-2.40	-1.58	-0.44	-1.01
EPS Diluted	-4.76	-0.94	-1.28	-1.37	-1.17	-2.40	-1.58	-0.44	-1.01
Weighted Average Basic Shares	96.51M	96.51M	96.05M	89.93M	91.31M	87.07M	85.94M	85.46M	85.23M
Weighted Average Diluted Shares	96.51M	96.51M	96.05M	89.93M	91.31M	87.07M	85.94M	85.46M	85.23M

Annual Income Statement (USD)

Swipe horizontally to review earlier years. The line-item column stays pinned.

Annual Report	12/31/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018
Revenue	3.51M	35.00M	370.00M	436K	913.08M	719K	289.59M	3.12M
Cost of Goods Sold	232.96M	110.25M	130.25M	110.25M	101.18M	269.41M	179.36M	113.77M
Gross Profit	-229.45M	-75.25M	239.75M	-109.81M	811.90M	-268.69M	110.23M	-110.65M
Gross Profit Margin	-6537.0%	-215.0%	64.8%	-25186.7%	88.9%	-37369.7%	38.1%	-3541.9%
Total Operating Expenses	338.87M	391.32M	462.29M	563.35M	438.38M	85.75M	63.49M	162.07M
Research & Development	265.33M	320.65M	387.33M	461.64M	340.57M	221.38M	179.36M	113.77M
Selling, General & Administrative	73.54M	72.98M	76.16M	102.46M	99.69M	85.75M	63.49M	48.29M
Operating Income (EBIT)	-568.32M	-466.57M	-222.54M	-673.16M	373.53M	-354.44M	46.74M	-158.94M
Operating Margin	-16191.4%	-1333.0%	-60.1%	-154394.7%	40.9%	-49295.5%	16.1%	-5087.8%
Income Before Tax (EBT)	-577.97M	-362.67M	-150.72M	-650.50M	379.53M	-348.06M	67.31M	-164.43M
Interest Income	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Other Income/Expense	-9.65M	103.90M	71.82M	22.66M	6.00M	6.38M	20.57M	-5.49M
Net Income	-581.60M	-366.25M	-153.61M	-650.17M	377.66M	-348.87M	66.86M	-164.98M
Income Tax Expense	3.63M	3.59M	2.89M	-325K	1.87M	809K	448K	553K
Net Profit Margin	-16569.8%	-1046.4%	-41.5%	-149122.7%	41.4%	-48520.9%	23.1%	-5281.1%
EBITDA	-548.84M	-447.31M	-202.70M	-648.99M	391.48M	-345.25M	51.47M	-155.42M
EBITDA Margin	-15636.4%	-1278.0%	-54.8%	-148850.7%	42.9%	-48018.2%	17.8%	-4975.2%
Depreciation & Amortization	19.48M	19.26M	19.84M	24.17M	17.95M	9.18M	4.72M	3.52M
EPS Basic	-6.47	-4.34	-1.94	-8.36	4.97	-5.29	1.23	-3.44
EPS Diluted	-6.47	-4.34	-1.94	-8.36	4.70	-5.29	1.17	-3.44
Weighted Average Basic Shares	89.93M	84.36M	79.22M	77.75M	75.95M	65.95M	54.39M	47.96M
Weighted Average Diluted Shares	89.93M	84.36M	79.22M	77.75M	80.39M	65.95M	56.93M	47.96M

Values are displayed in USD. Negative numbers shown in red.

Values are displayed in USD. Negative numbers are shown in red.